Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLA1 | P09884 | 1/20 | 0.77 |
| ▸ | CYP46A1 | Q9Y6A2 | 2/20 | 0.75 |
| ▸ | OSBP | P22059 | 3/20 | 0.71 |
| ▸ | USP2 | O75604 | 2/20 | 0.71 |
| ▸ | RORC | P51449 | 2/20 | 0.71 |
| ▸ | LMNA | P02545 | 1/20 | 0.71 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.71 |
| ▸ | OSBP2 | Q969R2 | 1/20 | 0.71 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.62 |
| ▸ | NPC1L1 | Q9UHC9 | 2/20 | 0.61 |
| ▸ | NPC1 | O15118 | 1/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.61 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.61 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.61 |
| ▸ | GBA1 | P04062 | 2/20 | 0.60 |
| ▸ | UGCG | Q16739 | 2/20 | 0.60 |
| ▸ | GBA2 | Q9HCG7 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL137969 | 0.98 | POLA1 (0.79) | POLA1CYP46A1OSBPUSP2RORC | |
| SCHEMBL6419070 | 0.98 | POLA1 (0.79) | POLA1CYP46A1OSBPUSP2RORC | |
| SCHEMBL17817630 | 0.96 | POLA1 (0.77) | POLA1CYP46A1OSBPUSP2RORC | |
| SCHEMBL3204391 | 0.96 | POLA1 (0.77) | POLA1CYP46A1OSBPUSP2RORC | |
| SCHEMBL13615226 | 0.96 | POLA1 (0.77) | POLA1CYP46A1OSBPUSP2RORC | |
| SCHEMBL23069792 | 0.96 | POLA1 (0.77) | POLA1CYP46A1OSBPUSP2RORC | |
| SCHEMBL249325 | 0.96 | POLA1 (0.77) | POLA1CYP46A1OSBPUSP2RORC | |
| SCHEMBL19608051 | 0.96 | POLA1 (0.77) | POLA1CYP46A1OSBPUSP2RORC | |
| SCHEMBL249326 | 0.96 | POLA1 (0.77) | POLA1CYP46A1OSBPUSP2RORC | |
| SCHEMBL16330224 | 0.94 | POLA1 (0.73) | POLA1CYP46A1OSBPUSP2RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260102283-A1 | PUNCTAL IMPLANTS, INSERTION SYSTEMS AND METHODS OF USING THE SAME | GLAUKOS CORP (US) | 2026-04-16 | — | — | US | disclosed |
| US-20260026967-A1 | MATERIALS AND METHODS FOR PUNCTAL PLUGS | GLAUKOS CORP (US) | 2026-01-29 | — | — | US | disclosed |
| EP-4041129-B1 | PUNCTAL IMPLANTS | GLAUKOS CORP (US) | 2025-12-03 | — | — | EP | disclosed |
| US-12453653-B2 | Materials and methods for punctal plugs | GLAUKOS CORPORATION (US) | 2025-10-28 | — | — | US | disclosed |
| EP-4337143-A1 | MATERIALS AND METHODS FOR PUNCTAL PLUGS | Glaukos Corporation (US) | 2024-03-20 | — | — | EP | disclosed |
| US-20240074897-A1 | PUNCTAL IMPLANTS, INSERTION SYSTEMS AND METHODS OF USING THE SAME | GLAUKOS CORP (US) | 2024-03-07 | — | — | US | disclosed |
| US-20230293344-A1 | PUNCTAL IMPLANTS WITH CONTROLLED DRUG DELIVERY FEATURES AND METHODS OF USING SAME | GLAUKOS CORP (US) | 2023-09-21 | — | — | US | disclosed |
| US-11564833-B2 | Punctal implants with controlled drug delivery features and methods of using same | GLAUKOS CORPORATION (US) | 2023-01-31 | — | — | US | disclosed |
| US-20220362055-A1 | MATERIALS AND METHODS FOR PUNCTAL PLUGS | GLAUKOS CORPORATION | 2022-11-17 | — | — | US | disclosed |
| WO-2022241266-A1 | MATERIALS AND METHODS FOR PUNCTAL PLUGS | GLAUKOS CORPORATION (US) | 2022-11-17 | — | — | WO | disclosed |
| EP-4041129-A1 | PUNCTAL IMPLANTS, INSERTION SYSTEMS AND METHODS OF USING THE SAME | Glaukos Corporation (US) | 2022-08-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260102283-A1 | PUNCTAL IMPLANTS, INSERTION SYSTEMS AND METHODS OF USING THE SAME | SSTR5, CFTR, STARD10 | POLA1 3456/4885CYP46A1 3721/4885OSBP 3329/4885 |
| US-20260026967-A1 | MATERIALS AND METHODS FOR PUNCTAL PLUGS | GHRHR, TIMCC, GNRHR | POLA1 4524/4885CYP46A1 1562/4885OSBP 3823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.